Endostar and/or Cisplatin for Treatment of Malignant Pleural Effusion or Ascites

A Randomized Controlled Multicenter Trial of Endostar and/or Cisplatin in Patients With Malignant Pleural Effusion or Ascites

The objective of this study is to compare the efficacy of Endostar/cisplatin with cisplatin alone or Endostar alone in patients with malignant pleural effusion or ascites.

Inclusion Criteria:

• Histological or cytological diagnosis of thoracic or abdominal tumor
• At least medium amount of malignant pleural effusion or ascites
• ECOG Performance Status 0-2
• Life expectancy ≥ 2 months
• Adequate hematologic, cardiac, renal, and hepatic function
• No major surgery within 4 weeks prior to this study
• Written informed consent

Exclusion Criteria:

• Patients with central nervous system (CNS) metastases
• Evidence of bleeding diathesis, serious infection
• Evidence of myocardial infarction, unstable angina or cardiac insufficiency
• Presence of serious COPD and/or respiratory failure
• Allergic to study drug
• Pregnant or lactating women
• Participation in other clinical trials within 30 days prior to this study